白细胞介素6阻断改变院外心脏骤停患者血浆代谢组
该研究为一项II期双盲随机试验(NCT 03863015)的子研究,纳入85例院外心脏骤停后昏迷患者,入院时随机接受托珠单抗8 mg/kg或安慰剂,其中80例接受干预且未退出。采用靶向代谢组学方法检测60种循环代谢物,分析随机化前和48小时后的血浆样本。结果显示,48小时时托珠单抗使血浆氨基酸(尤其是苏氨酸、甘氨酸和丝氨酸)水平升高超过1.5倍(p<0.01),两种类花生酸15(S)-HETE和12(S)-HETE升高1.9倍(p<0.01)。入院时三羧酸循环代谢物水平与自主循环恢复时间相关,并独立于早期IL-6水平;中链酰基肉碱早期水平与年龄、NT-proBNP、估算肾小球滤过率及神经损伤标志物神经丝轻链相关(均p<0.01)。
要点
- 在院外心脏骤停昏迷患者中,入院时随机给予托珠单抗8 mg/kg,48小时后血浆苏氨酸、甘氨酸和丝氨酸水平升高超过1.5倍(p<0.01)。
- 托珠单抗组48小时时两种类花生酸15(S)-HETE和12(S)-HETE水平为对照的1.9倍(p<0.01)。
- 入院时三羧酸循环代谢物水平与自主循环恢复时间相关,并独立于早期IL-6水平(均p<0.05)。
- 早期中链酰基肉碱水平与年龄、NT-proBNP、估算肾小球滤过率及神经丝轻链相关(均p<0.01)。
- 该研究为II期双盲随机试验的子研究,共80例患者纳入分析(托珠单抗组39例,安慰剂组41例)。
适用人群与场景
- 院外心脏骤停后复苏成功的昏迷患者,来自II期双盲随机试验(NCT 03863015)。
- 共85例随机,80例接受干预且未退出研究;中位年龄62岁(IQR 54-72),男性66例(83%)。
处置流程与药物剂量
- 入院时随机给予托珠单抗8 mg/kg或安慰剂;80例中39例分配至托珠单抗组,41例至安慰剂组。
- 随机化前和48小时后采集血浆样本,采用靶向代谢组学方法定量60种循环代谢物。
研究设计与关键结果
- 研究类型:II期双盲随机试验的子研究;样本量80例(托珠单抗组39例,安慰剂组41例);人群为院外心脏骤停后昏迷患者。
- 干预与对照:入院时托珠单抗8 mg/kg vs 安慰剂。
- 主要终点结果:48小时时托珠单抗使血浆氨基酸(尤其是苏氨酸、甘氨酸和丝氨酸)水平升高超过1.5倍(p<0.01);15(S)-HETE和12(S)-HETE水平为对照的1.9倍(p<0.01)。
- 入院时三羧酸循环代谢物水平与自主循环恢复时间相关,并独立于早期IL-6水平(均p<0.05)。
- 早期中链酰基肉碱水平与年龄、NT-proBNP、估算肾小球滤过率及神经丝轻链相关(均p<0.01)。
- 合并症和心脏骤停特征总体均衡。
证据类型、等级与局限
- 证据类型:II期双盲随机试验的子研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Comatose patients resuscitated from out-of-hospital cardiac arrest (OHCA) exhibit a systemic inflammatory response, as indicated by elevated interleukin-6 (IL-6) levels, which is associated with increased mortality. Tocilizumab, an IL-6 receptor antagonist that reduced C-reactive protein response and markers of myocardial injury in a phase II OHCA trial.
AIM: To describe the early effects of tocilizumab on circulating levels of metabolites in comatose patients resuscitated from OHCA.
METHOD: Patients from the phase-II double-blinded randomized trial (NCT: 03863015) were included in this substudy. A total of 85 comatose patients resuscitated from OHCA were randomized at the time of arrival to the hospital to either tocilizumab 8 mg/kg or placebo, of which 80 received the intervention and did not later withdraw from the study. Plasma samples before randomization and 48 h later were analyzed by a targeted metabolomics approach quantifying 60 circulating metabolites.
RESULTS: Of 80 enrolled patients (median age 62 years (IQR: 54-72), men 66 (83 %)), 39 were randomized to tocilizumab group and 41 to placebo. Comorbidities and cardiac arrest characteristics were overall well-balanced. At hospital arrival, levels of metabolites from the tricarboxylic acid (TCA) cycle were associated with time to return of spontaneous circulation and independently with early levels of IL-6 (all p < 0.05). The early levels of medium-chain acylcarnitines were associated with age, NT-proBNP, estimated glomerular filtration rate, and marker of neurological injury (neurofilament light chain) (all p < 0.01). At 48 h, tocilizumab increased the levels of plasma amino acids, especially threonine, glycine, and serine, by more than a factor of 1.5 (p < 0.01). Two eicosanoids 15(S)-HETE and 12(S)-HETE were 1.9 times higher (p < 0.01).
CONCLUSION: Blocking the IL-6 receptor with tocilizumab early after OHCA impacts circulating metabolites, particularly those within the glycine, serine, and threonine pathways, highlighting the connection between acute systemic inflammation and metabolism. Further, early levels of TCA metabolites are independently associated with early inflammatory response and early medium-chain acylcarnitine with later markers of neurological injury.
参考来源
- Paulin Beske R, Meyer MAS, Emil Roelsgaard Obling L, et al. Interleukin 6 blockage alters the plasma metabolome in out-of-hospital cardiac arrest. Resuscitation. 2024. PMID: 39510308. doi:10.1016/j.resuscitation.2024.110425
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。